Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.02
+0.16003.29%
Post-market: 5.050.0300+0.60%19:49 EDT
Volume:7.29M
Turnover:36.45M
Market Cap:324.14M
PE:-3.94
High:5.03
Open:4.81
Low:4.76
Close:4.86
52wk High:10.08
52wk Low:1.10
Shares:64.57M
Float Shares:54.41M
Volume Ratio:5.77
T/O Rate:13.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2729
EPS(LYR):-1.2729
ROE:-43.12%
ROA:-26.07%
PB:1.48
PE(LYR):-3.94

Loading ...

Immuneering price target raised to $30 from $21 at Oppenheimer

TIPRANKS
·
Sep 25, 2025

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Data Deluge

MT Newswires Live
·
Sep 25, 2025

Immuneering Announces $25M Securities Purchase Agreement

TIPRANKS
·
Sep 25, 2025

Immuneering Prices $175 Million Stock Offering

MT Newswires Live
·
Sep 25, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class a Common Stock and Concurrent $25 Million Private Placement of Class a Common Stock to Sanofi

THOMSON REUTERS
·
Sep 25, 2025

24H | Intel Jumps Another 3%; Opendoor Surges Another 11%; Immuneering Soars 39%; Stitch Fix Drops 2%

Tiger Newspress
·
Sep 25, 2025

BRIEF-Immuneering Announces Proposed Underwritten Public Offering Of Class A Common Stock

Reuters
·
Sep 25, 2025

BUZZ-Immuneering jumps after positive trial data for pancreatic cancer therapy

Reuters
·
Sep 25, 2025

Immuneering announces data from trial of atebimetinib combination

TIPRANKS
·
Sep 25, 2025

Immuneering announces Class A common stock offering, private placement

TIPRANKS
·
Sep 25, 2025

Immuneering Announces $25 Million Private Placement with Sanofi Alongside Proposed Public Offering of Class A Common Stock

Reuters
·
Sep 25, 2025

Immuneering Corp - Proceeds to Advance Preclinical and Clinical Development

THOMSON REUTERS
·
Sep 25, 2025

Immuneering Corp - Sanofi Agrees to Purchase $25 Mln of Immuneering Shares

THOMSON REUTERS
·
Sep 25, 2025

Immuneering Announces Proposed Underwritten Public Offering of Class a Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class a Common Stock and Class B Common Stock to Sanofi

THOMSON REUTERS
·
Sep 25, 2025

Immuneering Announces Extraordinary 86% 9-Month Survival in Phase 2a Pancreatic Cancer Trial, Plans Pivotal Phase 3 Launch by End of 2025

Reuters
·
Sep 25, 2025

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated With Atebimetinib + Mgnp

THOMSON REUTERS
·
Sep 25, 2025

Immuneering Corp - Expects Regulatory Feedback on Pivotal Trial Plans in Q4 2025

THOMSON REUTERS
·
Sep 25, 2025

Mizuho Securities Keeps Their Buy Rating on Immuneering (IMRX)

TIPRANKS
·
Sep 24, 2025